Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled Trial
23 avril 2026 mis à jour par: Gamze Öztürk, Istanbul University - Cerrahpasa
Effectiveness of Exercise Training Applied Through Virtual Reality in Patients With Pulmonary Hypertension
The goal of this research is to investigate the effectiveness of exercise administered via immersive virtual reality in patients with pulmonary hypertension, thereby contributing to the existing literature on this subject.
The main question is whether exercises delivered via immersive virtual reality are effective to improve physical performance, functional capacity, dyspnea, muscle strength, fatigue, quality of life, depression and anxiety.
Aperçu de l'étude
Statut
Inscription sur invitation
Les conditions
Intervention / Traitement
Description détaillée
The number of studies examining the effects of exercise training in pulmonary hypertension (PH) is limited in the literature.
Given the chronic nature of PH and the benefits of exercise in PH, the importance of exercise programs that include motivation as a factor becomes apparent.
Therefore, the aim of this research is to investigate the effectiveness of exercise programs implemented via virtual reality under the supervision of a physiotherapist in PH patients.
To investigators' knowledge, there are no studies in the literature examining the effectiveness of exercise training conducted via virtual reality in PH patients.
Therefore, another aim of this research is to identify virtual reality (VR) applications that can be used to improve clinical outcomes in PH patients and to contribute to the literature on the effectiveness of using innovative technologies in rehabilitation programs.
Type d'étude
Interventionnel
Inscription (Estimé)
32
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Fatih
-
Istanbul, Fatih, Turquie (Türkiye), 34180
- Istanbul University-Cerrahpaşa/ Cardiology Institute
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- Diagnosis of Idiopathic Pulmonary Arterial Hypertension,
- Stable pharmacological treatment for the past 3 months,
- Hemodynamic and clinical stability for at least the past three months,
- Age of 18-65,
- Voluntary participation in the study and signing the informed consent form,
- Being classified in the World Health Organization-Functional Classification I, II or III.
Exclusion Criteria:
- The presence of an orthopedic or neurological problem that will affect functional tests and muscle strength measurement,
- Acute decompensated heart failure,
- Unstable angina pectoris,
- Uncontrolled hypertension,
- The presence of problems that hinder communication,
- Dizziness, vertigo,
- Severe visual impairment,
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Virtual Reality Group
Patients assigned to Group 1 are involved in supervised exercise sessions 3 times a week during 8 weeks.
Exercise sessions includes aerobic and strengthed exercises delivered via virtual reality
|
Patients assigned to Group 2 are involved in supervised exercise sessions 3 times a week during 8 weeks.
Exercise sessions includes aerobic and strengthed exercises delivered via virtual reality
|
|
Aucune intervention: Control Group
Patients assigned to Group 2 will not included any intervention
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Muscle Strength
Délai: at the beginning of the study and at the end of 8 week,
|
Lower and upper extremity strength: Measurement is performed by having the person being tested exert maximum effort against the device during the measurement, and the person conducting the test respond with maximum force in the opposite direction to prevent movement.
The tests are repeated three times, and the average of the values is recorded in Newtons (N).
|
at the beginning of the study and at the end of 8 week,
|
|
Hand Grip Strength
Délai: at the beginning of the study and at the end of 8 weeks
|
The tests will be repeated three times, and the average of the values will be recorded in kilograms of force (kgF).
|
at the beginning of the study and at the end of 8 weeks
|
|
Functional capacity of lower extremity
Délai: at the beginning of the study and at the end of 8 weeks
|
Six Minute Walking Test: Participants will be asked to walk as fast as possible at their own pace for 6 minutes on a 30-meter course.
The distance walked by the patient will be recorded in meters.
|
at the beginning of the study and at the end of 8 weeks
|
|
Functional capacity of upper extremity
Délai: at the beginning of the study and at the end of 8 weeks
|
Six Minute Pegboard and Ring Test: A wooden platform with bars will be used during the test.
Two bars will be placed at shoulder level and the other two 20 cm above shoulder level.
Ten rings, each weighing 14 grams, will be placed on the lower bars: ten on the right and ten on the left, for a total of 20 rings.
Patients will be asked to place as many rings as possible from the lower bars to the upper bars and then back to the lower bars using both hands for 6 minutes.
At the end of this time, the number of rings moved will be recorded as the the total score, and the resting time will be recorded in seconds.
|
at the beginning of the study and at the end of 8 weeks
|
|
Physical performance
Délai: at the beginning of the study and at the end of 8 weeks
|
Short Physical Performance Battery: The test consists of 3 tests: walking 4 meters, standing up from a chair, and standing balance test. Each test is scored between 0-4. The scores obtained by the participants, ranging from 1-4, indicate the progressive performance required to complete the test according to the specified times. Walking test: Participants will be asked to walk 4 meters in a pre-marked corridor, and the time will be recorded and scored. The use of walking aids will be permitted, and saturation monitoring will be performed. Standing up from a chair test: Participants will be asked to stand up once from a seated position with their arms crossed over their chest. Patients who can do this will be asked to stand up and sit down five times as quickly as possible, and the time will be recorded. Standing balance test: 3 positions will be used; feet side-by-side and together, tandem, and half-tandem. |
at the beginning of the study and at the end of 8 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Dyspnea assessment
Délai: at the beginning of the study and at the end of the 8 weeks
|
Modified Medical Research Council Dyspnea Scale: This scale was developed to assess the level of dyspnea in patients.
The scale evaluates how much difficulty patients experience in daily life activities due to dyspnea.
Individuals indicate the degree of shortness of breath with a score between 0 and 4. Higher scores indicate a greater perception of dyspnea.
|
at the beginning of the study and at the end of the 8 weeks
|
|
Physical Activity Level Assessment
Délai: at the beginning of the study and at the end of 8 weeks
|
International Physical Activity Questionnaire - Short Form: This is a 7-question questionnaire developed to determine physical activity levels, covering the past week.
The questionnaire examines activities under the headings of vigorous physical activity, moderate physical activity, and walking.
All activities are recorded in terms of frequency (days/week) and duration (minutes/day).
A score in MET-min/week is calculated for all categories using a defined metabolic equivalent (MET) per activity, and the sum of these scores gives the total IPAQ-SF score.
Standard MET values are accepted as 3.3 for walking, 4.0 for moderate activity, and 8.0 for vigorous activity.
Sitting is assessed with a separate question and is not included in the total IPAQ-SF score.
|
at the beginning of the study and at the end of 8 weeks
|
|
Fatigue Assessment
Délai: at the beginning of the study and at the end of 8 weeks
|
Fatigue Severity Scale: The scale consists of 9 questions, each rated between 1 (strongly disagree) and 7 (strongly agree).
The total value is divided by 9 to obtain the final score.
An increased score indicates greater fatigue severity.
A score of <2.8 indicates no fatigue, while a score >6.1 indicates chronic fatigue.
|
at the beginning of the study and at the end of 8 weeks
|
|
Quality of life assessment
Délai: at the beginning of the study and at the end of 8 weeks
|
EmPHasis 10: Developed for assessing quality of life in patients diagnosed with pulmonary hypertension, the EmPHasis-10 includes inquiries about significant consequences of the disease, such as shortness of breath, fatigue, and lack of energy, which can also affect social life.
The scale consists of 10 questions, each a Likert-type question scored between 0 and 5.
The total score of the scale ranges from 0 to 50 points.
A high score indicates a poor quality of life due to symptoms.
|
at the beginning of the study and at the end of 8 weeks
|
|
Depression and anxiety assessment
Délai: at the beginning of the study and at the end of the 8 weeks
|
Hospital Anxiety and Depression Scale: The scale consists of 14 questions in total.
The Likert-type scale includes 7 questions to assess anxiety levels and 7 questions to assess depression levels.
Scores for both sub-assessments range from 0 to 21.
Higher scores indicate a worse level.
For both sub-assessments, scores of 0-7 indicate a normal level, 8-10 indicate borderline mood disorder, and ≥11 indicate a mood disorder.
|
at the beginning of the study and at the end of the 8 weeks
|
|
Virtual Reality Experience Assessment
Délai: at the beginning of the study and at the end of the 8 weeks
|
Simulator Sickness Questionnaire: This is a scale that assesses the safety of experiences that alter the perception of reality, such as virtual reality, and the symptoms of motion sickness.
It consists of 16 items grouped into 3 subscales (oculomotor symptoms, disorientation, nausea).
Each item is rated on a four-point scale (0 = I feel nothing, 1 = somewhat, 2 = moderate, and 3 = very), and the total score is the sum of the scores of the three subscales.
|
at the beginning of the study and at the end of the 8 weeks
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
31 janvier 2026
Achèvement primaire (Estimé)
1 janvier 2027
Achèvement de l'étude (Estimé)
1 janvier 2027
Dates d'inscription aux études
Première soumission
19 avril 2026
Première soumission répondant aux critères de contrôle qualité
23 avril 2026
Première publication (Réel)
30 avril 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
30 avril 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
23 avril 2026
Dernière vérification
1 avril 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2025/574
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
OUI
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .